GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (NAS:BRTX) » Definitions » Price-to-Free-Cash-Flow

BRTX (BioRestorative Therapies) Price-to-Free-Cash-Flow : N/A (As of Dec. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies Price-to-Free-Cash-Flow?

As of today (2024-12-15), BioRestorative Therapies's share price is $1.45. BioRestorative Therapies's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.14. Hence, BioRestorative Therapies's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for BioRestorative Therapies's Price-to-Free-Cash-Flow or its related term are showing as below:

BRTX's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 35.18
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

BioRestorative Therapies's Free Cash Flow per Share for the three months ended in Sep. 2024 was $-0.21. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.14.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 17.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 76.70% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 66.30% per year.

During the past 13 years, BioRestorative Therapies's highest 3-Year average Free Cash Flow per Share Growth Rate was 88.80% per year. The lowest was -162.80% per year. And the median was 48.50% per year.


BioRestorative Therapies Price-to-Free-Cash-Flow Historical Data

The historical data trend for BioRestorative Therapies's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioRestorative Therapies Price-to-Free-Cash-Flow Chart

BioRestorative Therapies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioRestorative Therapies Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioRestorative Therapies's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, BioRestorative Therapies's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioRestorative Therapies's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's Price-to-Free-Cash-Flow falls into.



BioRestorative Therapies Price-to-Free-Cash-Flow Calculation

BioRestorative Therapies's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1.45/-1.14
=N/A

BioRestorative Therapies's Share Price of today is $1.45.
BioRestorative Therapies's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.14.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

BioRestorative Therapies  (NAS:BRTX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


BioRestorative Therapies Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of BioRestorative Therapies's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


BioRestorative Therapies Business Description

Traded in Other Exchanges
Address
40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Executives
Dale Broadrick 10 percent owner 3003 BRICK CHURCH PIKE, NASHVILLE TN 37207
Francisco Silva director, 10 percent owner, officer: VP of Research and Development STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Lance Alstodt director, 10 percent owner, officer: President, CEO, COB BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Robert Eugene Kristal officer: Chief Financial Officer 4719 COLE AVENUE, DALLAS TX 75205
Patrick F. Williams director C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
David A Rosa director 10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Nickolay V. Kukekov director 4524 WESTWAY AVE, DALLAS TX 75205
Mark Weinreb director, 10 percent owner, officer: CEO and Chairman of the Board STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Paul Jude Tonna director 69 CHICHESTER ROAD, HUNTINGTON NY 11743
A. Jeffrey Radov director 8 WALWORTH AVENUE, SCARSDALE NY 10583
Robert Paccasassi officer: VP, Quality and Compliance C/O BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Robert B Catell director 62 OSBORNE ROAD, GARDEN CITY NY 11530
Adam D. Bergstein officer: SVP, Planning and Business Dev 167 HAZEL AVENUE, GLENCOE IL 60022
John M Desmarais director 230 PARK AVENUE, NEW YORK NY 10169
Westbury Trust 10 percent owner VICTORIA HALL, 11 VICTORIA STREET, P.O. BOX HM 1065, HAMILTON D0 00000

BioRestorative Therapies Headlines

From GuruFocus